These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29187747)

  • 1. Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals.
    Lammers A; Wang R; Cetnar J; Prasad V
    Blood Cancer J; 2017 Nov; 7(12):637. PubMed ID: 29187747
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic Drug Approvals Since the 1984 Hatch-Waxman Act.
    Gupta R; Kesselheim AS; Downing N; Greene J; Ross JS
    JAMA Intern Med; 2016 Sep; 176(9):1391-3. PubMed ID: 27428055
    [No Abstract]   [Full Text] [Related]  

  • 3. Unapproved Ophthalmic Drugs.
    Novack GD
    Ocul Surf; 2016 Apr; 14(2):317-20. PubMed ID: 27107659
    [No Abstract]   [Full Text] [Related]  

  • 4. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
    Roberts SA; Allen JD; Sigal EV
    Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
    Kim C; Prasad V
    JAMA Intern Med; 2015 Dec; 175(12):1992-4. PubMed ID: 26502403
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulating Off-Label Promotion - A Critical Test.
    Robertson C; Kesselheim AS
    N Engl J Med; 2016 Dec; 375(24):2313-2315. PubMed ID: 27805841
    [No Abstract]   [Full Text] [Related]  

  • 7. [Off-label use in oncology. The Italian choice].
    Felicetti V; Gremigni U; Cifaldi L
    Recenti Prog Med; 2008 Dec; 99(12):612-5. PubMed ID: 19388222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.
    DeLoughery EP; Prasad V
    Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605
    [No Abstract]   [Full Text] [Related]  

  • 9. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA approvals and label changes.
    AIDS Patient Care STDS; 2009 Jul; 23(7):578-9. PubMed ID: 19621996
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 12. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment.
    Albrecht J; Adamson AS; Barbieri JS; Bennett DD; Kiracofe EA; Kourosh AS; Leslie KS; Merola JF; Nguyen J; Siegfried E; Strickland N; Olbricht S; Asgari MM;
    J Am Acad Dermatol; 2019 Feb; 80(2):577-578. PubMed ID: 30244066
    [No Abstract]   [Full Text] [Related]  

  • 14. The strange allure of state "right-to-try" laws.
    Zettler PJ; Greely HT
    JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
    [No Abstract]   [Full Text] [Related]  

  • 15. An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
    Hey SP; Kesselheim AS
    PLoS Med; 2016 Mar; 13(3):e1001978. PubMed ID: 26978686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated approval of oncology drugs: can we do better?
    Ellenberg SS
    J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of drug-approval regulations for medical countermeasures against CBRN agents in Japan.
    Shimazawa R; Ikeda M
    Health Secur; 2015; 13(2):130-8. PubMed ID: 25813978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA may allow more conditional drug approvals.
    J Am Vet Med Assoc; 2014 Nov; 245(9):992. PubMed ID: 25470840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.